HER2 Targeted Molecular MR Imaging Using a De Novo Designed Protein Contrast Agent 英文参考文献.docVIP

下载本文档

6
0
约3.73万字
约 9页
2017-05-11 发布于上海
举报
版权申诉

HER2 Targeted Molecular MR Imaging Using a De Novo Designed Protein Contrast Agent 英文参考文献.doc

1、本文档共9页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

HER2 Targeted Molecular MR Imaging Using a De Novo Designed Protein Contrast Agent 英文参考文献

HER2TargetedMolecularMRImagingUsingaDeNovo DesignedProteinContrastAgent JingjuanQiao1,ShunyiLi1,LixiaWei2,JieJiang1,RobertLong3,HuiMao3,LingWei1,LiyaWang3, HuaYang4,HansE.Grossniklaus4,Zhi-RenLiu2*,JennyJ.Yang1* 1Department of Chemistry, Georgia State University, Atlanta, Georgia, United States of America, 2Department of Biology, Georgia State University, Atlanta, Georgia, UnitedStatesofAmerica,3DepartmentofRadiology,EmoryUniversity,Atlanta,Georgia,UnitedStatesofAmerica,4DepartmentofOphthalmology,EmoryUniversity SchoolofMedicine,Atlanta,Georgia,UnitedStatesofAmerica Abstract Theapplicationofmagneticresonanceimaging(MRI)tonon-invasivelyassessdiseasebiomarkershasbeenhamperedby the lack of desired contrast agents with high relaxivity, targeting capability, and optimized pharmacokinetics. We have developedanovelMRimagingprobetargetingtoHER2,abiomarkerforvariouscancertypesandadrugtargetforanti- cancertherapies.ThismultimodalHER20targetedMRimagingprobeintegratesadenovodesignedproteincontrastagent withahighaffinityHER2affibodyandanearIRfluorescentdye.Ourprobecandifferentiallymonitortumorswithdifferent expression levels of HER2 in both human cell lines and xenograft mice models. In addition to its 100-fold higher dose efficiency compared to clinically approved non-targeting contrast agent DTPA, our developed agent also exhibits advantages in crossing the endothelial boundary, tissue distribution, and tumor tissue retention over reported contrast agentsasdemonstratedbyevendistributionoftheimagingprobeacrosstheentiretumormass.Thiscontrastagentwill provideapowerfultoolforquantitativeassessmentofmolecularmarkers,andimprovedresolutionfordiagnosis,prognosis anddrugdiscovery. Citation:QiaoJ,LiS,WeiL,JiangJ,LongR,etal.(2011)HER2TargetedMolecularMRImagingUsingaDeNovoDesignedProteinContrastAgent.PLoSONE6(3): e18103.doi:10.1371/journal.pone.0018103 Editor:QuanshengDu,MedicalCollegeofGeorgia,UnitedStatesofAmerica ReceivedDecember17,2010;AcceptedFebruary21,2011;PublishedMarch24,2011 C